We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -4.44% | 5.375 | 5.25 | 5.50 | 5.625 | 5.375 | 5.625 | 1,268,205 | 14:37:32 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.20 | 6.18M |
TIDMGDR
RNS Number : 5094A
Genedrive PLC
26 September 2022
genedrive plc
("genedrive" or the "Company")
NICE to accelerate evaluation of the Genedrive (R) MT-RNR1 Test
New Early Value Assessment Programme identifies technologies more rapidly
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK's National Institute for Health and Clinical Excellence ("NICE") has transferred the evaluation of the Genedrive(R) MT-RNR1 test to a new Early Value Assessment Programme ("EVA"). EVA is a new review process, created to drive innovation into the hands of healthcare professionals by actively drawing in digital products, medical devices and diagnostics that address national unmet needs.
The EVA allows the NICE diagnostics advisory committee to consider the technology much faster, which will result in a published report in a six month timeframe instead of the initial 63 weeks (approximately 14 months) via the Diagnostics Assessment Programme. A provisional schedule has been published by NICE which indicates the consultation process will occur in February 2023.
The Genedrive(R) MT-RNR1 assay is the world's first rapid point-of-care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive(R) test.
David Budd, CEO of genedrive plc, said: "We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive(R) MT-RNR1 test has been fast tracked via their new EVA programme, which may allow clinicians and patients to benefit from the test sooner. This is a testament to our technology and our ability to address this unmet need."
For further details please contact:
genedrive plc +44 (0)161 989 0245 David Budd: CEO / Russ Shaw: CFO Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900 James Steel finnCap (Joint Broker) +44 (0)20 7220 0500 Geoff Nash / Alice Lane Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com Relations) +44 (0)7980 541 893 / +44 (0)7876 Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on the market for the detection of MT-RNR1, HCV, certain military biological targets, a high throughput SARS-CoV-2 assay and a point of care test for Covid-19.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RESUORVRUUUKUAR
(END) Dow Jones Newswires
September 26, 2022 02:00 ET (06:00 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions